Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Effect of the p38 MAPK inhibitor SB-239063 on Lipopolysaccharide-induced psychomotor retardation and peripheral biomarker alterations in rats.

Bison S, Razzoli M, Arban R, Michielin F, Bertani S, Carboni L.

Eur J Pharmacol. 2011 Jul 1;661(1-3):49-56. doi: 10.1016/j.ejphar.2011.04.020.

PMID:
21545800
2.

SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung.

Underwood DC, Osborn RR, Bochnowicz S, Webb EF, Rieman DJ, Lee JC, Romanic AM, Adams JL, Hay DW, Griswold DE.

Am J Physiol Lung Cell Mol Physiol. 2000 Nov;279(5):L895-902.

3.

SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence.

Underwood DC, Osborn RR, Kotzer CJ, Adams JL, Lee JC, Webb EF, Carpenter DC, Bochnowicz S, Thomas HC, Hay DW, Griswold DE.

J Pharmacol Exp Ther. 2000 Apr;293(1):281-8.

4.
5.

Effects of a dual inhibitor of tumor necrosis factor-alpha and interleukin-1 on lipopolysaccharide-induced lung injury in rats: involvement of the p38 mitogen-activated protein kinase pathway.

Yoshinari D, Takeyoshi I, Koibuchi Y, Matsumoto K, Kawashima Y, Koyama T, Ohwada S, Morishita Y.

Crit Care Med. 2001 Mar;29(3):628-34.

PMID:
11373433
6.

Anti-inflammatory effect and selectivity profile of AS1940477, a novel and potent p38 mitogen-activated protein kinase inhibitor.

Terajima M, Inoue T, Magari K, Yamazaki H, Higashi Y, Mizuhara H.

Eur J Pharmacol. 2013 Jan 5;698(1-3):455-62. doi: 10.1016/j.ejphar.2012.11.021.

PMID:
23183108
7.

A p38alpha selective mitogen-activated protein kinase inhibitor prevents periodontal bone loss.

Kirkwood KL, Li F, Rogers JE, Otremba J, Coatney DD, Kreider JM, D'Silva NJ, Chakravarty S, Dugar S, Higgins LS, Protter AA, Medicherla S.

J Pharmacol Exp Ther. 2007 Jan;320(1):56-63.

9.

A p38 mitogen-activated protein kinase inhibitor arrests active alveolar bone loss in a rat periodontitis model.

Rogers JE, Li F, Coatney DD, Otremba J, Kriegl JM, Protter TA, Higgins LS, Medicherla S, Kirkwood KL.

J Periodontol. 2007 Oct;78(10):1992-8.

PMID:
18062121
10.

Interleukin-6 and leptin mediate lipopolysaccharide-induced fever and sickness behavior.

Harden LM, du Plessis I, Poole S, Laburn HP.

Physiol Behav. 2006 Sep 30;89(2):146-55.

PMID:
16842830
11.

Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia.

Barone FC, Irving EA, Ray AM, Lee JC, Kassis S, Kumar S, Badger AM, Legos JJ, Erhardt JA, Ohlstein EH, Hunter AJ, Harrison DC, Philpott K, Smith BR, Adams JL, Parsons AA.

Med Res Rev. 2001 Mar;21(2):129-45. Review.

PMID:
11223862
12.
13.

Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models.

Jackson JR, Bolognese B, Hillegass L, Kassis S, Adams J, Griswold DE, Winkler JD.

J Pharmacol Exp Ther. 1998 Feb;284(2):687-92.

14.

Differences in the relative involvement of peripherally released interleukin (IL)-6, brain IL-1β and prostanoids in mediating lipopolysaccharide-induced fever and sickness behavior.

Harden LM, du Plessis I, Roth J, Loram LC, Poole S, Laburn HP.

Psychoneuroendocrinology. 2011 Jun;36(5):608-22. doi: 10.1016/j.psyneuen.2010.09.003.

PMID:
20926198
15.

Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity.

Hill RJ, Dabbagh K, Phippard D, Li C, Suttmann RT, Welch M, Papp E, Song KW, Chang KC, Leaffer D, Kim YN, Roberts RT, Zabka TS, Aud D, Dal Porto J, Manning AM, Peng SL, Goldstein DM, Wong BR.

J Pharmacol Exp Ther. 2008 Dec;327(3):610-9. doi: 10.1124/jpet.108.139006.

16.

Pharmacological profile of AW-814141, a novel, potent, selective and orally active inhibitor of p38 MAP kinase.

Chopra P, Kulkarni O, Gupta S, Bajpai M, Kanoje V, Banerjee M, Bansal V, Visaga S, Chatterjee M, Chaira T, Shirumalla RK, Verma AK, Dastidar SG, Sharma G, Ray A.

Int Immunopharmacol. 2010 Apr;10(4):467-73. doi: 10.1016/j.intimp.2010.01.007.

PMID:
20093202
17.

DBM1285 suppresses tumor necrosis factor alpha production by blocking p38 mitogen-activated protein kinase/mitogen-activated protein kinase-activated protein kinase 2 signaling pathway.

Kang JS, Kim HM, Choi IY, Han SB, Yoon YD, Lee H, Park KH, Cho IJ, Lee CW, Lee K, Lee KH, Park SK.

J Pharmacol Exp Ther. 2010 Aug;334(2):657-64. doi: 10.1124/jpet.109.161687.

18.

Alcohol consumption attenuates febrile responses to lipopolysaccharide and interleukin-1 beta in male rats.

Taylor AN, Tio DL, Heng NS, Yirmiya R.

Alcohol Clin Exp Res. 2002 Jan;26(1):44-52.

PMID:
11821653
Items per page

Supplemental Content

Support Center